2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4277 Outcomes of relapse following allogeneic blood or marrow transplant (alloBMT) in acute lymphoblastic leukemia (ALL) including the contribution of subsequent cellular therapies

Madison Reed, MD, BS, Mark J. Levis I, MD PhD2, B. Douglas Smith, MD3, Ivana Gojo, MD4, Alexander Joseph Ambinder, MD, MPH5, Amy DeZern, MD, MHS6, Gabrielle T. Prince, MD7, Tania Jain, MBBS8, Javier Bolanos-Meade, MD9, Lukasz P. Gondek, MD, PhD10, Gabriel Ghiaur, MD, PhD11, William Brian Dalton, MD, PhD12, Theodoros Karantanos, MD, PhD13, Suman Paul, PhD, MBBS14, Ephraim Fuchs, MD15, Jorge Florindez, MD16, Cole H Sterling, MD17, Richard Ambinder, MD, PhD18, Christian Burris Gocke, MD, PhD19, Philip Imus, MD20, Syed Abbas Ali, MBBS21, Carol Huff, MD22, Richard John Jones, MD23, Jonathan Allen Webster, MD24
1 Yale University, New Haven, Connecticut, United States
2 Johns Hopkins University, Baltimore, Maryland, United States
3 Johns Hopkins University, Baltimore, Maryland, United States
4 Johns Hopkins University, Baltimore, Maryland, United States
5 Johns Hopkins University, Baltimore, Maryland, United States
6 Johns Hopkins University, Baltimore, Maryland, United States
7 Johns Hopkins University, Baltimore, Maryland, United States
8 Johns Hopkins University, Baltimore, Maryland, United States
9 Johns Hopkins University, Baltimore, Maryland, United States
10 Johns Hopkins University, Baltimore, Maryland, United States
11 Johns Hopkins University, Baltimore, Maryland, United States
12 Johns Hopkins University, Baltimore, Maryland, United States
13 Johns Hopkins University, Baltimore, Maryland, United States
14 Johns Hopkins University, Baltimore, Maryland, United States
15 Johns Hopkins University, Baltimore, Maryland, United States
16 Johns Hopkins University, Baltimore, Maryland, United States
17 Johns Hopkins University, Baltimore, Maryland, United States
18 Johns Hopkins University, Baltimore, Maryland, United States
19 Johns Hopkins University, Baltimore, Maryland, United States
20 Johns Hopkins University, Baltimore, Maryland, United States
21 Johns Hopkins University, Baltimore, Maryland, United States
22 Johns Hopkins University, Baltimore, Maryland, United States
23 Johns Hopkins University, Baltimore, Maryland, United States
24 Johns Hopkins University, Baltimore, Maryland, United States

Background:  The therapeutic landscape in ALL has changed dramatically over the last decade. Reductions in post-transplant relapse largely attributed to the pre-transplant eradication of measurable residual disease with blinatumomab and later generation tyrosine kinase inhibitors for Philadelphia chromsome-positive (Ph+) disease have meaningfully improved alloBMT outcomes. Large, retrospective studies of post-alloBMT relapse that predate recent therapeutic advances demonstrate dismal outcomes with 5-year overall survival (OS) of just 8% (Spyridonidis. Leukemia. 2012).  We sought to understand patterns of post-transplant relapse, subsequent therapies, and outcomes.          

  

Methods:  The alloBMT database at Johns Hopkins was queried for adult patients (age ≥18) undergoing a first transplant from January 2008-January 2026. Relapse was defined as ≥5% lymphoblasts in the bone marrow or peripheral blood or the appearance of lymphoblasts in an extramedullary (EM) site including the central nervous system (CNS).  For relapsed patients, data was collected regarding subsequent therapies, response to therapy, subsequent transplant, and the use of alternative cellular therapies.  Estimators of OS and relapse-free survival (RFS) were reported using the Kaplan-Meier method. Differences in time-to-event outcomes were estimated using Cox proportional hazards model, or Fine and Gray's model for cumulative incidence of relapse (CIR)/non-relapse mortality (NRM) considering competing risks.

 

Results:  A total of 336 patients underwent a first alloBMT for ALL including 146 for Ph- B ALL, 141 for Ph+ B ALL, and 49 for T ALL. The 5-year CIR for the whole cohort was 29% (95% CI 24-34%) with a higher incidence in T ALL [49% (95% CI 32-64%)] than Ph- B ALL [30.4% (95% CI 23-38%)] or Ph+ B ALL [21% (95% CI 14-28%)]. There were a total of 94 relapses with a median time from transplant to relapse of 10.9 months (range 1-146 months). The median age at relapse was 45 years (range 22-74). Among the relapses, 61% involved bone marrow/peripheral blood (BM/PB) only, 19% were isolated CNS relapses, 13% were isolated non-CNS EM relapses, 3% involved both the CNS and BM/PB, and 3% involved both EM sites and the BM/PB.

 

Among 93 relapsed patients for whom data were available, 85 received subsequent, non-palliative therapy, while 8 patients elected hospice or palliative treatment alone. Eighty-two patients were assessed for subsequent remission with 67% achieving CR. Among B ALL patients who received subsequent therapy, 58% and 23% of those who relapsed after the approval of blinatumomab and inotuzumab, respectively, received those therapies. Sixteen B ALL patients received either one (13) or two (3) CAR T cell therapies with 87.5% achieving CR. Thirty-three patients (10 T ALL and 23 B ALL), representing 60% of those who achieved CR, underwent subsequent alloBMT. The majority of patients (94%) received reduced-intensity conditioning with grafts from HLA-matched unrelated (6), haploidentical (20), and HLA-mismatched unrelated donors (7). Post-transplantation cyclophosphamide was a component of graft-versus-host disease prophylaxis for most patients (94%).    

 

The 3-year OS following post-transplant relapse was 34% (95% CI 24-44%) with better survival in those who relapsed >6 months post-transplant (HR 0.37, 95% CI 0.22-0.61, p=0.0001). There were no appreciable differences in post-relapse OS based on disease phenotype or site of relapse. For patients who underwent a subsequent alloBMT in CR (n=33), 3-year RFS from the time of transplant was 40% (95% CI 23-56%) with a CIR of 36% (95% CI 20-52%) and NRM of 25% (95% CI 12-41%).  The 3-year OS was 53% (95% CI 34-68%). The 3-year RFS was the same for B ALL (23) and T ALL (10) patients who underwent a subsequent alloBMT. Eleven B ALL patients received CAR T cell therapy and achieved CR after relapse following a first (6) or second (5) alloBMT without plans for further consolidation with transplant, the 3-year RFS following CAR T therapy was 64% (95% CI 30-84%) in this cohort.      

 

Conclusions:  Long-term survival among ALL patients with post-transplant relapse has improved with modern therapy. For patients who achieve remission, consolidation with alloBMT is a curative option. While alternative consolidation options are not available in T ALL, CAR T cell therapy without subsequent alloBMT yields promising long-term outcomes in patients who retain targetable antigen expression.  

Jonathan Allen Webster, MD: Autolus - Honoraria; Syndax - Honoraria; Rigel - Honoraria; Amgen - Honoraria; AstraZeneca - Honoraria; CVS - Consultancy (Includes expert testimony)